Risks associated with Mycophenolate Mofetil and COVID-19
Immunosuppressive drugs like MMF can lead to increased susceptibility of patients to infections. Patients taking MMF as part of their treatment plan are considered high risk and advised to undertake increased precautionary measures against COVID-19. Renal, cardiac and hepatic transplant patients taking MMF are considered vulnerable and should be managed with facilities staffed with adequate resources with support therapy and treatment to reduce mortality associated with COVID-19. Moreover, it can also lead to development of lymphoma in solid organ transplant patients [18-19].